Lale Tokgözoğlu: Significant CV Benefit of Lowering LDL to 44 mg/dL in Diabetes
Lale Tokgözoğlu, Professor of Cardiology at Hacettepe University, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Our analysis from the Vesalius trial showed significant benefit of lowering LDL to a median of 44 mg/dL in diabetics presented at ACC26.”
Title: Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial
Authors: Nicholas A. Marston, Erin A. Bohula, Ajay K. Bhatia, Gaetano M. De Ferrari, Lawrence A. Leiter, Jose C. Nicolau, Jeong-Gun Park, Sabina A. Murphy, Emileigh Walsh, Lyrica Liu, Subodh Verma, Naveed Sattar, Stephen J. Nicholls, Jose Lopez-Sendon, Ioanna Gouni-Berthold, Lale Tokgozoglu, Ron Blankstein, Marcoli Cyrille, Gabriel Paiva da Silva Lima, Robert P. Giugliano, Marc S. Sabatine
Read the Full Article on Jama

More posts featuring Lale Tokgözoğlu on Hemostasis Today
-
Nov 19, 2026, 22:24Erik Nelson: Low Iron Can Raise A1c without Changing Blood Sugar
-
Nov 19, 2026, 22:23Erwin Loh: Daily Iron Supplementation Reduces Iron-Deficiency Anaemia in Children and Adolescents
-
Nov 19, 2026, 22:22Afifah Sardar: Why Can a Simple Painkiller like Aspirin Make You Bleed More?
-
Nov 19, 2026, 22:16Jonathan Penm: Perioperative Anticoagulation Management and Antithrombotic Stewardship Across 31 Countries
-
Nov 19, 2026, 22:15Salomao V.: Innovation in Hemophilia A Is Also About How Patients Receive Their Treatment
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing